See more : PT Summarecon Agung Tbk (SMRA.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Progyny, Inc. (PGNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Progyny, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Invitae Corporation (NVTA) Income Statement Analysis – Financial Results
- Modern Living Investments Holdings Limited (8426.HK) Income Statement Analysis – Financial Results
- Eagle Bulk Shipping Inc. (EGLE) Income Statement Analysis – Financial Results
- Greif, Inc. (GEF) Income Statement Analysis – Financial Results
- Cineplex Inc. (CPXGF) Income Statement Analysis – Financial Results
Progyny, Inc. (PGNY)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.progyny.com
About Progyny, Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 786.91M | 500.62M | 344.86M | 229.68M | 105.40M | 48.58M |
| Cost of Revenue | 849.80M | 619.59M | 388.49M | 274.80M | 184.18M | 85.97M | 41.18M |
| Gross Profit | 238.80M | 167.33M | 112.14M | 70.06M | 45.51M | 19.43M | 7.40M |
| Gross Profit Ratio | 21.94% | 21.26% | 22.40% | 20.32% | 19.81% | 18.44% | 15.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 117.13M | 98.33M | 59.62M | 46.71M | 23.93M | 15.60M | 14.15M |
| Selling & Marketing | 59.49M | 45.66M | 20.18M | 15.01M | 11.90M | 7.29M | 4.26M |
| SG&A | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Other Expenses | 0.00 | 286.00K | -366.00K | 210.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Cost & Expenses | 1.03B | 763.57M | 468.28M | 336.51M | 220.01M | 108.85M | 59.59M |
| Interest Income | 0.00 | 814.00K | 461.00K | 121.00K | 58.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 814.00K | 461.00K | 121.00K | 58.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 2.28M | 1.60M | 1.30M | 1.91M | 2.13M | 1.88M | 1.56M |
| EBITDA | 64.47M | 24.94M | 33.64M | 10.25M | 11.81M | -1.57M | -9.45M |
| EBITDA Ratio | 5.92% | 3.17% | 6.72% | 2.97% | 13.06% | 1.30% | -17.97% |
| Operating Income | 62.18M | 23.34M | 32.34M | 8.35M | 27.85M | -3.45M | -11.01M |
| Operating Income Ratio | 5.71% | 2.97% | 6.46% | 2.42% | 12.13% | -3.28% | -22.65% |
| Total Other Income/Expenses | 8.51M | 1.10M | 95.00K | 331.00K | -18.23M | -3.44M | -1.45M |
| Income Before Tax | 70.69M | 24.44M | 32.44M | 8.68M | -8.56M | -6.89M | -12.46M |
| Income Before Tax Ratio | 6.49% | 3.11% | 6.48% | 2.52% | -3.73% | -6.54% | -25.64% |
| Income Tax Expense | 8.65M | -5.92M | -33.33M | -37.78M | 12.00K | -1.78M | -3.00K |
| Net Income | 62.04M | 30.36M | 65.77M | 46.46M | -8.57M | 661.00K | -12.45M |
| Net Income Ratio | 5.70% | 3.86% | 13.14% | 13.47% | -3.73% | 0.63% | -25.63% |
| EPS | 0.65 | 0.33 | 0.74 | 0.54 | -0.10 | 0.01 | -0.18 |
| EPS Diluted | 0.62 | 0.30 | 0.66 | 0.47 | -0.10 | 0.01 | -0.15 |
| Weighted Avg Shares Out | 95.02M | 92.20M | 89.11M | 85.72M | 83.57M | 81.56M | 70.59M |
| Weighted Avg Shares Out (Dil) | 100.67M | 99.96M | 100.36M | 99.06M | 83.57M | 81.56M | 81.56M |
Did Progyny, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- PGNY
NEW YORK, NY / ACCESSWIRE / September 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with...
PGNY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Progyny, Inc. and Encourages Investors to Contact the Firm!
NEW YORK , Sept. 22, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ: PGNY).
Lost Money on Progyny, Inc.(PGNY)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / September 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with...
Bronstein, Gewirtz & Grossman, LLC Encourages Progyny, Inc. (PGNY) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to...
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Progyny, Inc. (PGNY)
NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with...
PGNY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Progyny, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. (“Progyny” or “the Company”) (NASDAQ: PGNY). Investors who purchased Progyny securities are encouraged to obtain...
The Law Offices of Frank R. Cruz Announces Investigation of Progyny, Inc. (PGNY) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Progyny, Inc. (“Progyny” or the “Company”) (NASDAQ: PGNY) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who...
Lost Money on Progyny, Inc. (PGNY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with...
Levi & Korsinsky Reminds Progyny, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - PGNY
NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Progyny, Inc. (PGNY) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / September 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to...
Source: https://incomestatements.info
Category: Stock Reports